Does Vyvanse Cause Weight Loss? Honest Evidence Review

The honest answer: yes, Vyvanse causes weight loss — but the FDA has explicitly refused to approve it for that purpose, and using it as a weight-loss tool is a serious clinical error when GLP-1 receptor agonists exist. Vyvanse (lisdexamfetamine dimesylate) is a Schedule II amphetamine prodrug FDA-approved only for two indications: attention-deficit/hyperactivity disorder (ADHD) in patients ages 6 and older, and moderate-to-severe binge eating disorder (BED) in adults. The FDA Vyvanse label states verbatim that “VYVANSE is not indicated or recommended for weight loss” and that “the safety and effectiveness of VYVANSE for the treatment of obesity have not been established.” The label carries a Boxed Warning for abuse, misuse, and addiction, and lisdexamfetamine is a DEA Schedule II controlled substance — the same legal category as oxycodone, morphine, and fentanyl. In the pivotal 12-week BED trials (McElroy 2016^[2], Studies 11 + 12, n=745) that won Vyvanse its BED indication, decreased weight occurred in 4% of Vyvanse patients vs 0% of placebo — the FDA chose those trials to support a BED indication, not a weight-loss indication, for specific clinical reasons. Below: the actual magnitude of weight loss in BED and ADHD trials, the verbatim FDA-label warnings, why GLP-1 receptor agonists are a dramatically safer and more effective tool for obesity, and why off-label Vyvanse-for-weight-loss prescribing has drawn DEA scrutiny in the 2023–2025 telehealth-stimulant landscape.

TL;DR — Vyvanse and weight

• Vyvanse is FDA-approved only for ADHD (ages 6+) and moderate-to-severe binge eating disorder (BED) in adults — not for weight loss. The FDA Vyvanse label states explicitly: “VYVANSE is not indicated or recommended for weight loss.”
• Vyvanse does cause weight loss, but the magnitude is modest and dose-dependent. In the FDA Vyvanse label, “decreased weight” appeared as an adverse reaction in 3% of adult ADHD patients (Study 7) and 4% of adult BED patients (Studies 11 + 12) vs 0% of placebo. In a pediatric ADHD trial (Study 1, 4 weeks), mean weight loss was −0.9 to −2.5 pounds depending on dose, compared to +1 pound on placebo.
• Schedule II controlled substance. Lisdexamfetamine is in the same DEA scheduling category as oxycodone, morphine, methylphenidate, and other amphetamines. Prescriptions are limited to a 30-day supply with no refills; transmitted prescriptions require prescription- monitoring-program reporting in most states.
• Boxed Warning for abuse, misuse, and addiction. The FDA label warns verbatim: “VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death.”
• Cardiovascular risk profile. The FDA label requires monitoring of blood pressure and heart rate; increased blood pressure (3%) and increased heart rate (2–7% across populations) are listed adverse reactions. The label warns to “avoid use” in patients with structural cardiac disease, coronary artery disease, or serious arrhythmia.
• GLP-1 receptor agonists deliver dramatically more weight loss with a different risk profile. Wegovy delivered −14.9% total body-weight loss at 68 weeks in STEP-1^[10]; Zepbound delivered −20.9% at 72 weeks in SURMOUNT-1^[11]. Neither is a controlled substance. For obesity itself, GLP-1s are first-line; off-label stimulants are not.
• Off-label Vyvanse-for-weight-loss prescribing has drawn DEA scrutiny. During the 2023–2025 adult-ADHD-medication shortages, telehealth platforms that prescribed stimulants outside their FDA-approved indications (including for weight loss) faced federal investigation.

What Vyvanse is

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug of d-amphetamine. The lisdexamfetamine molecule itself is pharmacologically inactive — it is the amino acid L-lysine covalently bonded to d-amphetamine. After oral ingestion, red blood cells and intestinal enzymes cleave the lysine-amphetamine bond to release active d-amphetamine into systemic circulation. The Hutson 2014 prodrug pharmacology paper ^[5] documents that this enzymatic-release design produces a smoother, longer-duration plasma d-amphetamine curve than immediate-release amphetamine, with lower abuse liability via non-oral routes (snorting or injecting the prodrug doesn’t produce a rapid euphoric peak, because the d-amphetamine still has to be enzymatically released). Despite that engineering, the FDA still classifies Vyvanse as a Schedule II controlled substance — the same designation as immediate-release amphetamine (Adderall), methylphenidate (Ritalin), oxycodone, morphine, and fentanyl.

Vyvanse capsules are available in 10, 20, 30, 40, 50, 60, and 70 mg strengths; chewable tablets in matching strengths. Standard dosing in adult ADHD is 30–70 mg once daily in the morning; standard dosing in adult BED is 50–70 mg once daily (the 30 mg/day dose was not statistically different from placebo in the Phase 2 BED dose-finding study, McElroy 2015^[1], which is why the BED label dose range starts at 50 mg). Vyvanse was first FDA-approved in 2007 for ADHD and received the BED indication in January 2015 — the only stimulant FDA-approved for any eating- disorder indication.

What the FDA Vyvanse label actually says

From the Vyvanse package insert (DailyMed, Takeda Pharmaceuticals USA), the directly relevant verbatim text:

Indications and Usage: “VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [and] Moderate to severe binge eating disorder (BED) in adults.”

Limitations of Use: “VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established.”

Boxed Warning — Abuse, Misuse, and Addiction: “VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.”

Schedule II / Section 9.1: “VYVANSE contains lisdexamfetamine, a Schedule II controlled substance.”

Contraindications: “Known hypersensitivity to amphetamine products or other ingredients in VYVANSE. Use with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose.”

Risks to Patients with Serious Cardiac Disease: “Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Monitor blood pressure and pulse.”

Read the “Limitations of Use” section twice. The FDA is doing two specific things in those three sentences. First, it’s telling prescribers that despite Vyvanse having a well-documented weight-loss adverse-reaction signal, the agency reviewed the evidence and chose not to approve it for weight loss. Second, it’s reminding prescribers about the historical context: previous-generation sympathomimetic anorectic drugs (fenfluramine + phentermine “fen-phen,” phenmetrazine, sibutramine, amfepramone) were removed from the market or restricted after serious cardiovascular and pulmonary-hypertension events when used for weight loss. The FDA is explicitly invoking that history.

Where to verify: the Vyvanse package insert lives on DailyMed at SetID 704e4378-ca83-445c-8b45-3cfa51c1ecad. Use DailyMed, not accessdata.fda.gov — the latter 404s silently when label revisions ship.

The BED pivotal trials — what was actually measured

Vyvanse won its BED indication on the basis of three randomized controlled trials cited verbatim in the FDA label as Study 10, Study 11, and Study 12. The McElroy 2015 JAMA Psychiatry Phase 2 study^[1] (Study 10) tested 30, 50, and 70 mg/day vs placebo over 11 weeks (3 weeks forced-dose titration followed by 8 weeks of dose maintenance) in adults with moderate-to-severe BED. The primary endpoint was reduction in binge days per week. The 30 mg/day dose was not statistically different from placebo; the 50 and 70 mg/day doses were statistically superior. That dose-response finding is why the FDA-approved BED dose range starts at 50 mg/day, not the 30 mg/day where ADHD dosing can begin.

The pivotal McElroy 2016 Neuropsychopharmacology paper ^[2] reported the two 12-week Phase 3 randomized, double-blind, placebo-controlled, dose-optimization trials referenced in the FDA label as Studies 11 (n=374) and 12 (n=350). The primary endpoint, again, was the change in binge days per week — not weight. Lisdexamfetamine significantly reduced binge days vs placebo in both trials. The adverse-reaction data from these pooled trials (n=373 Vyvanse vs n=372 placebo) is what populates Table 4 of the FDA label:

BED placebo-controlled adverse reactions (12-week, Studies 11 + 12 pooled, ≥2% incidence and at least twice placebo): Dry Mouth 36% vs 7%; Insomnia 20% vs 8%; Decreased Appetite 8% vs 2%; Increased Heart Rate 7% vs 1%; Feeling Jittery 6% vs 1%; Constipation 6% vs 1%; Anxiety 5% vs 1%; Diarrhea 4% vs 2%; Decreased Weight 4% vs 0%; Hyperhidrosis 4% vs 0%.

The Hudson 2017 JAMA Psychiatry randomized-withdrawal trial ^[3] followed BED patients who had responded to 12 weeks of open-label lisdexamfetamine, then re-randomized them to continued lisdexamfetamine vs placebo for 26 weeks. Lisdexamfetamine significantly delayed time to BED relapse vs placebo. The Grilo 2024 Psychol Med paper^[4] examined whether lisdexamfetamine added benefit as maintenance therapy following an initial successful behavioral or pharmacological response to BED.

Three things to take from the BED trial corpus. First, the primary endpoint was always binge-eating reduction, not body weight. Weight loss was a secondary measure and an adverse-reaction signal. Second, BED-indicated dosing has not been validated for weight loss in non-BED populations. Patients without a DSM-IV/V BED diagnosis were not enrolled in these trials, and the effect sizes documented in moderate-to-severe BED do not automatically generalize to general obesity. Third, the FDA reviewed the same trial data and chose to add the explicit “not indicated for weight loss” limitation to the label. Off-label Vyvanse-for-weight-loss prescribing is asking a Schedule II amphetamine to do something the FDA specifically refused to authorize despite having the data.

The adult ADHD weight signal

In the FDA Vyvanse label, the adult ADHD pivotal trial cited as Study 7 (Adler 2008^[6], n=358 Vyvanse vs n=62 placebo, 4 weeks) reported the following adverse reactions at ≥2% and at least twice placebo:

Adult ADHD placebo-controlled adverse reactions (4-week, Study 7): Decreased Appetite 27% vs 2%; Dry Mouth 26% vs 3%; Insomnia 27% vs 8%; Diarrhea 7% vs 0%; Nausea 7% vs 0%; Anxiety 6% vs 0%; Anorexia 5% vs 0%; Increased Blood Pressure 3% vs 0%; Decreased Weight 3% vs 0%; Increased Heart Rate 2% vs 0%.

The 12-month open-label safety extension (Weisler 2009, Study 304^[8]) documented sustained mean weight loss in adults on long-term lisdexamfetamine for ADHD — but mean weight loss in that population was measured in single-digit pounds, not the 15–20% TBWL magnitudes delivered by GLP-1 receptor agonists. The Adler 2009 J Clin Psychiatry analysis of cardiovascular parameters ^[7] documented small but consistent increases in systolic blood pressure, diastolic blood pressure, and resting heart rate on lisdexamfetamine vs placebo — the same cardiovascular pattern the FDA label invokes when it warns against use in serious cardiac disease.

The pediatric ADHD label data is included for completeness because it’s where the dose-response weight effect is clearest. From the verbatim FDA label, Study 1 (4 weeks, ages 6–12):

“Mean weight loss from baseline after 4 weeks of therapy was −0.9, −1.9, and −2.5 pounds, respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 1 pound weight gain for patients receiving placebo.”

Translated: at the highest pediatric ADHD dose (70 mg/day) over 4 weeks, the placebo-corrected weight change was approximately −3.5 pounds (about −1.6 kg). That is the rough acute-phase magnitude on a stimulant amphetamine prodrug at the upper end of FDA-approved dosing.

Mechanism — why amphetamines reduce appetite

Once enzymatically cleaved, lisdexamfetamine releases d-amphetamine. D-amphetamine acts on presynaptic dopamine and norepinephrine transporters: it reverses the direction of these transporters, pushing dopamine and norepinephrine out of the presynaptic neuron into the synaptic cleft. The net effect is increased dopamine and norepinephrine signaling across multiple brain regions:

• Hypothalamic appetite circuits. Norepinephrine activity in the lateral hypothalamus and paraventricular nucleus suppresses food intake. Dopamine activity in the arcuate nucleus modulates reward-driven eating (the “wanting” component of food reward, separate from homeostatic hunger).
• Prefrontal-cortex executive control. Increased catecholaminergic tone in the prefrontal cortex improves impulse control — the mechanism by which stimulants treat ADHD. In BED, this same effect is hypothesized to reduce impulsive binge episodes.
• Peripheral sympathetic activation. Increased systemic norepinephrine raises heart rate, blood pressure, and basal metabolic rate. The cardiovascular warnings on the Vyvanse label trace directly to this mechanism.

This catecholaminergic appetite-suppression mechanism is the same general pharmacology behind older anorectic drugs (phentermine, diethylpropion, phenmetrazine, fenfluramine). It works — in the sense that average food intake goes down and average weight goes down — but it carries the sympathomimetic-cardiovascular signature the FDA label flags, and it operates fundamentally differently from the GLP-1 receptor agonists, which act primarily on the gut-brain satiety axis rather than central catecholamines.

Magnitude: Vyvanse vs phentermine vs Wegovy vs Zepbound

Cross-trial caveat: figures above are drawn from independent trials of different populations, designs, durations, and primary endpoints. They are not head-to-head comparisons and cannot be used to predict individual outcomes. The Vyvanse BED row reflects the McElroy 2016 ^[2] placebo-controlled trial magnitude approximated to a percent-of-baseline scale. The Khera 2016 JAMA^[9] meta-analysis values are the 1-year placebo-subtracted weight losses reported in that paper for the FDA-approved anti-obesity medications at the time. The Wegovy and Zepbound values are the 68- and 72-week placebo-subtracted total body-weight loss from STEP-1 ^[10] and SURMOUNT-1^[11].

Two observations from the chart. First, even at the most generous reading of the Vyvanse BED data, the magnitude is on the same order as 12-week phentermine and meaningfully smaller than the 1-year results of FDA-approved anti-obesity medications. Second, both GLP-1 receptor agonists (Wegovy and Zepbound) deliver multiples of the weight loss Vyvanse produces, and neither is a controlled substance. When a patient and a clinician are choosing a weight-loss intervention, the relevant question isn’t whether Vyvanse can lower weight (it can); the question is what the alternatives offer at the same risk level. The risk-benefit calculus does not favor Schedule II amphetamines for weight loss when GLP-1 receptor agonists are available.

DEA Schedule II implications

Lisdexamfetamine is a Schedule II controlled substance under the Controlled Substances Act — the same scheduling category as oxycodone, morphine, methylphenidate, dextroamphetamine, methamphetamine, cocaine, and fentanyl. Schedule II status carries specific practical implications for prescribers, patients, and pharmacies:

• 30-day supply maximum, no refills. Federal law prohibits refills on Schedule II prescriptions. Each prescription is a new prescription, requiring a fresh clinician encounter or documented chart review.
• Prescription Drug Monitoring Program (PDMP) reporting. Most US states require Schedule II prescriptions to be reported to a PDMP, which is accessible to other prescribers, pharmacies, and (in some states) law enforcement.
• Pharmacy-level inventory tracking and DEA audits. Pharmacies must maintain detailed biennial inventories of Schedule II stock. DEA audits and shortage-driven supply disruptions (notably 2022–2025 for amphetamines) trace directly to this regulatory layer.
• Telehealth prescribing restrictions in flux. The federal “Ryan Haight Online Pharmacy Consumer Protection Act” restricts remote-only prescribing of Schedule II substances. Pandemic-era flexibilities were extended multiple times through 2024 and 2025; the future regulatory landscape continues to evolve. Multiple telehealth-stimulant platforms drew DEA scrutiny in the 2023–2025 period.
• Dependence is part of the label. The Vyvanse label includes Section 9.3 on dependence, consistent with the amphetamine class. Chronic dosing produces neurochemical adaptation; abrupt cessation can produce withdrawal symptoms including fatigue, dysphoria, and rebound appetite (which by itself often produces rebound weight gain).

None of this is incompatible with appropriate use of Vyvanse for its FDA-approved indications. ADHD and moderate-to-severe BED are real conditions with real benefits from lisdexamfetamine treatment. The point is that the regulatory scaffolding around Schedule II prescribing was designed because amphetamines have abuse and dependence liability that non-controlled medications do not. Choosing a Schedule II amphetamine over a non-controlled GLP-1 receptor agonist for weight loss reverses the risk-stratification logic the FDA and DEA built.

Off-label Vyvanse-for-weight-loss prescribing

Despite the FDA label’s explicit “not indicated or recommended for weight loss” statement, off-label prescribing of Vyvanse (and Adderall) for weight loss has been documented in:

• Telehealth stimulant-prescribing platforms that surged during the 2020–2023 pandemic. Several venture-funded telehealth platforms allowing rapid online stimulant prescriptions drew DEA scrutiny and federal investigation; in 2023–2024, at least one major platform’s founders faced criminal charges related to alleged stimulant-prescribing-pattern violations.
• Weight-loss clinics with concierge cash-pay models. Some retail weight-loss clinics have prescribed phentermine, phendimetrazine (Schedule III), or off-label lisdexamfetamine/amphetamine for weight loss outside FDA-approved obesity-medication pathways.
• Patients self-treating for “weight loss + focus” during the 2022–2025 amphetamine shortages. The well-documented Adderall and Vyvanse shortages of 2022–2025 created a downstream market for diverted and unregulated supply — not a safe path.

Off-label prescribing is legal in the US under most circumstances, but it carries distinct considerations for Schedule II amphetamines that don’t apply to most other off-label uses. The FDA-approved obesity pharmacotherapy landscape now includes Qsymia (phentermine + topiramate), Contrave (naltrexone + bupropion), Wegovy, and Zepbound — with two or three more on the horizon. The off-label-stimulant-for- weight-loss rationale has eroded substantially as these alternatives have arrived.

When weight loss reverses

The amphetamine-mediated weight-loss effect is not durable without continued dosing, and continued dosing carries the tachyphylaxis and dose-escalation patterns that helped define the “diet pill” problem of earlier decades:

• Tolerance to the appetite-suppression effect. Chronic dopaminergic and noradrenergic stimulation downregulates receptor sensitivity. Acute-phase appetite suppression of weeks 1–4 often gives way to a recovered appetite by month 3–6, requiring either dose escalation or acceptance of the diminished effect.
• Dose escalation pressure. When the appetite-suppression effect fades, patients and prescribers face pressure to increase the dose. The FDA-approved maximum is 70 mg/day; off-label or diverted higher dosing carries proportionally higher cardiovascular and abuse risk.
• Post-discontinuation rebound. Abrupt discontinuation of chronic amphetamine therapy commonly produces hyperphagia (the “crash” phase documented in both the recreational stimulant and the clinical-stimulant-withdrawal literatures). Rebound appetite typically drives rebound weight gain over 3–9 months, often exceeding the weight that was lost.
• Long-term cardiovascular accumulation. The small per-day increases in systolic BP, diastolic BP, and resting heart rate documented by Adler 2009 ^[7] accumulate over years on therapy. The FDA label requires periodic monitoring for this reason.

By contrast, GLP-1 receptor agonist trials at 1–2 years (STEP, SURMOUNT, SELECT) document weight stabilization rather than tachyphylaxis, and discontinuation rebound, while real, occurs on a different mechanistic footing.

Vyvanse + GLP-1: anecdote, not evidence

Some patients are prescribed both an amphetamine stimulant (Vyvanse for ADHD or BED) and a GLP-1 receptor agonist (Wegovy or Zepbound for obesity). No randomized controlled trial has examined this combination for weight outcomes, and the FDA labels for Wegovy, Ozempic, Mounjaro, and Zepbound do not list any pharmacokinetic interaction with lisdexamfetamine. Practical considerations:

• Overlapping appetite suppression. Both drug classes reduce food intake by independent mechanisms. Acute combined nausea (from the GLP-1) and acute combined appetite suppression (from both) can drop intake to medically unsafe levels in the first 4–8 weeks of dual initiation. Stagger dose escalations.
• Cardiovascular monitoring matters more, not less. Vyvanse raises heart rate and blood pressure; GLP-1 receptor agonists raise resting heart rate modestly. The combined cardiovascular profile has not been systematically studied in obesity populations.
• Serotonin syndrome risk if also on SSRIs. Stimulant + SSRI combinations carry a small but real serotonin-syndrome risk. If a patient is on a GLP-1, an SSRI for depression or anxiety, and a stimulant, the interaction layer multiplies. See our review of how Wellbutrin XL stacks with the GLP-1 mechanism and Paxil’s anticholinergic + SSRI weight profile for related drug-drug considerations.
• The relevant question is whether the stimulant should be on board at all. If the indication is ADHD or BED, yes — the FDA-approved indication stands. If the de facto indication is weight loss, the GLP-1 is doing the obesity work and the stimulant is adding cardiovascular load, abuse liability, and DEA scheduling overhead without added weight benefit at any documented magnitude that justifies the trade-off.

Stopping Vyvanse safely

Vyvanse can be discontinued without a formal taper in most patients — unlike SSRIs, benzodiazepines, or opioids, amphetamines don’t produce a defined withdrawal syndrome with autonomic instability. What patients do experience on discontinuation, particularly after months or years of daily dosing:

• Fatigue, drowsiness, lethargy (1–3 weeks; the “crash”)
• Dysphoria, anhedonia, low motivation (variable, can persist 4–12 weeks)
• Rebound hyperphagia — recovered or increased appetite that frequently produces weight regain over 3–9 months
• Concentration / executive-function difficulties (in ADHD patients, return of baseline symptoms)
• Sleep changes — commonly initial hypersomnia, then normalization

None of these is medically dangerous in itself, but the rebound-hyperphagia + weight-regain pattern is the specific reason that “use Vyvanse for a few months to lose weight then stop” is a clinical anti-strategy. The weight comes back, and the patient is left with a 3–9 month post-discontinuation dysphoria period that GLP-1 discontinuation does not produce.

For patients on long-term high-dose Vyvanse contemplating discontinuation for any reason, dose tapering over 2–6 weeks under prescribing-clinician supervision is the standard approach, primarily to soften the rebound-hyperphagia and rebound-fatigue phases rather than to prevent a withdrawal syndrome. Never discontinue Vyvanse abruptly without clinical guidance, particularly at doses >50 mg/day or after long-term continuous use.

Common bad takes

“Doctors prescribe Vyvanse for weight loss all the time, so it must be fine.” Frequency of off-label prescribing is not a measure of safety or evidence support. Off-label use of Schedule II amphetamines for weight loss is documented but explicitly discouraged by the FDA Vyvanse label and drew federal investigation in the 2023–2025 telehealth-stimulant period.

“Vyvanse is approved for binge eating, so it’s safe for obesity in general.” Wrong. The FDA Vyvanse label states verbatim: “The safety and effectiveness of VYVANSE for the treatment of obesity have not been established.” BED is a specific DSM-5 diagnosis (recurrent binge episodes, marked distress, no compensatory behaviors). The pivotal Vyvanse BED trials enrolled only patients meeting BED criteria. Effect sizes and safety findings from a BED population don’t automatically transfer to general obesity, and the FDA specifically chose not to extend the indication.

“GLP-1s have side effects too, so the risk-benefit favors Vyvanse.” The risk profiles are not comparable. GLP-1 receptor agonists are not controlled substances, have no abuse liability or dependence pattern, and produced 14.9–20.9% TBWL in their pivotal trials — multiples of what Vyvanse produces. Their adverse-reaction profile (predominantly GI: nausea, vomiting, constipation) is largely transient and manageable. Schedule II amphetamines carry cardiovascular, abuse, and dependence risks that no GLP-1 carries.

“I’ll just take Vyvanse for 3 months to drop 20 pounds, then stop.” The rebound-hyperphagia pattern after stimulant discontinuation almost always restores the lost weight over 3–9 months — often with additional gain. The trial data does not support a “short course of Vyvanse for weight” strategy, and the FDA label does not authorize it.

“Vyvanse and Adderall are basically the same thing.” Pharmacologically related but not identical. Vyvanse is a prodrug requiring enzymatic cleavage to release d-amphetamine; Adderall is a mixture of d- and l-amphetamine salts (75/25). Vyvanse has a slower- onset, longer-duration plasma curve and theoretically lower abuse liability via non-oral routes — but both are Schedule II amphetamines, both carry the same Boxed Warning, and neither is FDA-approved for weight loss. See our companion piece on Vyvanse + Adderall + GLP-1 stacking for the multi-drug landscape.

Bottom line

• Vyvanse is FDA-approved only for ADHD (ages 6+) and moderate-to-severe BED in adults — NOT for weight loss. The FDA Vyvanse label states: “VYVANSE is not indicated or recommended for weight loss. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established.”
• Yes, Vyvanse does cause weight loss — modest, dose-dependent, mediated by d-amphetamine release. The FDA label documents 27% decreased appetite (vs 2% placebo) and 3% decreased weight (vs 0% placebo) in adult ADHD trials, and 8% decreased appetite (vs 2% placebo) and 4% decreased weight (vs 0% placebo) in adult BED trials over 12 weeks.
• Schedule II controlled substance + Boxed Warning for abuse, misuse, and addiction. Same DEA scheduling as oxycodone, morphine, fentanyl. 30-day supply maximum, no refills, PDMP reporting.
• Cardiovascular risk profile requires monitoring. The FDA label warns against use in serious cardiac disease and requires periodic blood-pressure and pulse monitoring.
• GLP-1 receptor agonists are dramatically more effective for weight loss with a different (and generally better- tolerated) risk profile. Wegovy: −14.9% TBWL at 68 wk; Zepbound: −20.9% TBWL at 72 wk. Neither is a controlled substance. For obesity, GLP-1s are first-line.
• Off-label Vyvanse-for-weight-loss prescribing is not supported by the trial data the FDA reviewed. The FDA had the same Vyvanse BED data and explicitly chose not to approve a weight-loss indication. Off-label stimulant prescribing for weight loss has drawn DEA scrutiny in the 2023–2025 period.
• Post-discontinuation rebound hyperphagia and weight regain are the rule, not the exception. A short course of Vyvanse for weight loss is not a viable strategy — the weight comes back.

Related research

• Vyvanse + Adderall + GLP-1: the stimulant-stack landscape
• Qsymia (phentermine + topiramate) weight-loss evidence
• Contrave (naltrexone + bupropion) weight-loss evidence
• Lomaira (phentermine 8 mg) average weight-loss evidence
• How to get a phentermine prescription online: FDA-approved pathways
• Can you take phentermine with a GLP-1?
• Wellbutrin XL for weight loss: how fast and how much?
• Does Paxil cause weight loss? Honest evidence review
• GLP-1 side-effect questions answered

Important disclaimer. This article is educational and does not constitute medical advice. Vyvanse (lisdexamfetamine) is a Schedule II controlled substance FDA-approved only for ADHD (ages 6+) and moderate-to-severe binge eating disorder in adults; it is not FDA-approved for weight loss or obesity, and the FDA Vyvanse label explicitly warns that “the safety and effectiveness of VYVANSE for the treatment of obesity have not been established.” Decisions about starting, stopping, or continuing any stimulant medication belong with a qualified prescribing clinician who knows your full cardiac, psychiatric, and substance-use history. Off-label stimulant prescribing for weight loss has drawn federal regulatory scrutiny; nothing in this article endorses that practice.